Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2007
05/31/2007US20070122502 Therapeutic juice composition for women
05/31/2007US20070122491 Methods and compositions for altering cell function
05/31/2007US20070122490 Wound healing compound
05/31/2007US20070122484 Parenterally administrable microparticles
05/31/2007US20070122481 Rapid dissolving tablets containing capecitabine and releasing the drug in pulses about six to about twelve hours after administration
05/31/2007US20070122479 Threo-DOPS controlled release formulation
05/31/2007US20070122478 Extended release composition containing tramadol
05/31/2007US20070122477 Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency
05/31/2007US20070122476 Storage stable thyroxine active drug formulations and methods for their production
05/31/2007US20070122475 Taste masking composition
05/31/2007US20070122474 Pharmaceutical preparation comprising an active dispersed on a matrix
05/31/2007US20070122473 Aminosugar and/or glycosaminoglycan composition having therapeutic use
05/31/2007US20070122470 New Combination Dosage Form
05/31/2007US20070122468 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
05/31/2007US20070122467 Anaesthetic formulations
05/31/2007US20070122465 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
05/31/2007US20070122464 Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis
05/31/2007US20070122463 Antimicrobial compositions and wound dressings
05/31/2007US20070122458 Nicotine and Chocolate Compositions
05/31/2007US20070122457 Nicotine and Chocolate Compositions
05/31/2007US20070122456 Nicotine and Cocoa Powder Compositions
05/31/2007US20070122452 Fat composition
05/31/2007US20070122448 Compositions and methods to create a vascularized environment for cellular transplantation
05/31/2007US20070122447 Shaped bodies and methods for their production and use
05/31/2007US20070122444 Medical devices employing triazine compounds and compositions thereof
05/31/2007US20070122443 Amphiphilic copolymer compositions
05/31/2007US20070122435 Topical dapsone for the treatment of acne
05/31/2007US20070122426 Composition containing fractionated bee propolis
05/31/2007US20070122419 Methods and compositions for treating atherosclerosis
05/31/2007US20070122418 Compositions and methods for the pulmonary delivery of aerosolized medicaments
05/31/2007US20070122414 Surface marker-directed cancer therapeutics
05/31/2007US20070122412 Eg-vegf nucleic acids and polypeptides and methods of use
05/31/2007US20070122400 Composition having liver function protecting effect
05/31/2007US20070122399 Nutraceutical formulation for healing human bone due to accidental fracture or surgical replacement or grafting, containing lysine, proline, ascorbic acid, copper, and vitamin B6
05/31/2007US20070122379 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
05/31/2007US20070122377 Compositions and methods of treatment
05/31/2007US20070122375 Bile acid sequestrant and process for preparation thereof
05/31/2007US20070122367 Resorcinol derivatives
05/31/2007US20070122366 Preparations for the care nails that contain Terbinafine hydrochloride
05/31/2007US20070122355 Rapidly absorbing oral formulations of pde 5 inhibitors
05/31/2007US20070122352 Inhalation Drug Combinations
05/31/2007US20070122351 Inhalation Drug Combinations
05/31/2007US20070122350 Safe and effective methods of administering therapeutic agents
05/31/2007US20070122348 For preventing oral abuse of an oral opioid formulation; provides a negative, "aversive" experience when a large amount of the opioid, e.g., about 2-3 times the usually prescribed dose, is taken by or administered to a physically dependent subject
05/31/2007US20070122340 Necrosis avid tracer agent
05/31/2007DE69133083C5 Behandlung und Vorbeugung von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten Treatment and prevention mediated by elevated lyso-PAF mirror mental disorders with PAF antagonists
05/31/2007DE102005057421A1 New heteroaromatic sulfonamide prodrugs, useful for delivering e.g. antimalarials and steroids for e.g. fertility control or hormone replacement therapy
05/31/2007DE102005057408A1 New sulfamoylsulfonate prodrugs e.g. useful for protecting red blood cells from attack by parasites or for hormone replacement therapy, female fertility control or treating hormone-associated diseases
05/31/2007DE102005057225A1 New 8-beta-substituted estratriene derivatives esterified with a sulfamoylphenyl-substituted acid residue, are prodrugs useful as carboanhydrase inhibitors for treating estrogen deficiency disorders
05/31/2007DE102005057224A1 New 9-alpha substituted estratriene derivatives esterified with a sulfamoylphenyl-substituted acid residue, are prodrugs useful as carboanhydrase inhibitors for treating estrogen deficiency disorders
05/31/2007DE102005056558A1 Kombinationspräparate enthaltend physiologische Zellmembran-Bestandteile Combination products containing physiological cell membrane components
05/31/2007DE102005055961A1 Pharmaceutical composition containing specific concentration of quaternary ammonium anticholinergic agent, useful for treatment, by inhalation, of respiratory tract diseases
05/31/2007DE102005050376A1 Dicarbonsäure-Derivate und ihre Verwendung Dicarboxylic acid derivatives and their use
05/31/2007DE102005049954A1 Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen Triazolopyridine derivatives as inhibitors of lipases and phospholipases
05/31/2007DE102005047564A1 New forms of specific substituted thiophene carboxamide (rivaroxaban), useful for prevention and treatment of thromboembolic disease, have higher solubility than known modifications
05/31/2007CA2824517A1 Nuclear receptor binding agents
05/31/2007CA2824307A1 F, g, h, i and k crystal forms of imatinib mesylate
05/31/2007CA2824301A1 F, g, h, i and k crystal forms of imatinib mesylate
05/31/2007CA2633549A1 Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis
05/31/2007CA2632090A1 Selected dosage for the treatment of cardiovascular and related pathologies
05/31/2007CA2631408A1 Composition having effect on treatment and prevention of dry eye syndrome
05/31/2007CA2631331A1 Nuclear receptor binding agents
05/31/2007CA2631241A1 Materials and methods for treating viral infections with a cysteamine compound
05/31/2007CA2631121A1 Use of guanabenz and its derivatives for making drugs for treating cystic fibrosis and diseases related to a protein addressing deficiency in the cells
05/31/2007CA2631082A1 Oncogenic ras-specific cytotoxic compound and methods of use thereof
05/31/2007CA2631017A1 Bisboron compounds for use as intracellular calcium concentration increase inhibitors
05/31/2007CA2631014A1 Compositions useful for reducing nephrotoxicity and methods of use thereof
05/31/2007CA2630935A1 Beta glycolipids as immuno-modulators
05/31/2007CA2630907A1 Pyrazoloisoquinoline derivatives
05/31/2007CA2630900A1 Use of parp-1 inhibitors
05/31/2007CA2630860A1 Urea derivatives useful as calcium receptor modulators
05/31/2007CA2630848A1 Use of 3-iodo-l-phenylalanine or 4-iodo-l-phenylalanine in the treatment of malignant neoplasia
05/31/2007CA2630818A1 Pharmaceutical composition for prevention or treatment of neurogenic pain
05/31/2007CA2630816A1 Pharmaceutical comprising ppar agonist
05/31/2007CA2630805A1 Salicylic acid derivatives
05/31/2007CA2630752A1 Method of modulating stress-activated protein kinase system
05/31/2007CA2630741A1 Glyceryl ether compounds and their use
05/31/2007CA2630738A1 Immunostimulatory oligoribonucleotides
05/31/2007CA2630718A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/31/2007CA2630714A1 S1p receptor modulating compounds and use thereof
05/31/2007CA2630699A1 Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
05/31/2007CA2630668A1 Intraocular pressure-regulated early genes and uses thereof
05/31/2007CA2630655A1 Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor
05/31/2007CA2630639A1 Treatment of qt interval prolongation and diseases associated therewith
05/31/2007CA2630617A1 Compositions and methods for modulating gated ion channels
05/31/2007CA2630562A1 Tricyclic compounds useful as inhibitors of kinases
05/31/2007CA2630551A1 N-hydroxyamide derivatives and use thereof
05/31/2007CA2630465A1 Antineoplastic compounds
05/31/2007CA2630459A1 Substituted azacycloalkanes useful for treating cns conditions
05/31/2007CA2630324A1 Process for synthesizing remifentanil
05/31/2007CA2630271A1 Fused bicyclic mtor inhibitors
05/31/2007CA2630254A1 New pleuromutilin derivative and its use
05/31/2007CA2630234A1 Thrombopoietin activity modulating compounds and methods
05/31/2007CA2630222A1 Carbamate compounds as 5-ht4 receptor agonists
05/31/2007CA2630148A1 Methods of treating ischemic related conditions
05/31/2007CA2630147A1 Compositions for disrupting and inhibiting reconstitution of wound biofilm
05/31/2007CA2630117A1 Calcilytic compounds
05/31/2007CA2630072A1 Pharmaceutical compositions comprising buprenorphine
05/31/2007CA2630054A1 High-potency sweetener composition with phytosterol and compositions sweetened therewith
05/31/2007CA2630049A1 Natural high-potency sweetener compositions with improved temporal profile and/or flavor profile, methods for their formulation, and uses
1 ... 3732 3733 3734 3735 3736 3737 3738 3739 3740 3741 3742 3743 3744 3745 3746 3747 3748 3749 3750 3751 3752 ... 7860